Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07556796 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of IBI3016 in People With Mild or Moderate Hypertension Patients

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting Start date changed from estimate of May 15, 2026 to May 8, 2026 · Eligibility criteria expanded, about 14 words · Site contact updated Show 3 more changesShow less
    • Start date changed from estimate of May 15, 2026 to May 8, 2026
    • Eligibility criteria expanded, about 14 words
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.
Trial Details
NCT Number NCT07556796
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Hypertension
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov